Clinical Trial

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a study for patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to standard treatment with gemcitabine. The study will also try to identify the best dose of MK-3475 to give in combination with gemcitabine.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2015-04-20; most recent amendment 2026-01-30.
Status change: Recruiting → Active, Not Recruiting 2018-10-08
Trial Details
NCT Number NCT02422381
Lead Sponsor Providence Health & Services
Collaborators: Merck Sharp & Dohme LLC, Providence Cancer Center, Earle A. Chiles Research Institute
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 16 participants
Start Date 2015-07-20
Primary Completion 2019-01-09 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-18